articleThe Lancet OncologyOct 23, 2009GREEN OA

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Mayo Clinic · Mayo Clinic in Florida · +9 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

933
total citations
FWCI
42.69
Percentile
100%
References
35
Citations per year

Authors

10

Topics & keywords

Keywords
  • Medicine
  • Lenalidomide
  • Dexamethasone
  • Multiple myeloma
  • Clinical endpoint
  • Thalidomide
  • Internal medicine
  • Interim analysis
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding